Public Funding for Lindus Health Limited

Combining innovations in machine learning and data science and with relevance to all 35K human clinical trials performed globally each year, Lindus aim to develop the first software solution capable of automated real time clinical trial data capture, analysis and prediction - exploiting known gaps in clinical data management (defined as the collection, integration and validation of trial data). The approach has been specifically designed to address stated challenges cited by trial sponsors (typically represented by pharmaceutical and biotech companies) in response to an increasing demand for fast-track drug development processes, a drive for improved patient safety and improved quality of data outputs. The approach significantly advances current clinical data management processes which centre around manual paper-based data input and electronic data capture with interpretation typically performed retrospectively (in some cases months after trial completion), providing greater risk of issues in data quality and an inability to identify risks/quality/safety issues as and when they occur. With the potential to accelerate delivery and reduce clinical trial costs (by up to 25%), the proposed solution offers significant growth potential as a disruptive innovation that fully meets the needs of trial sponsors and regulators. It will be exploited globally by an established but fast-growing contract research organisation who have pioneered the use of AI in clinical trial design and delivery as part of an established end-to-end trial delivery platform (existing functions include study design, patient recruitment capability and trial management) with a range of customers ready to adopt the product. Innovate UK support will accelerate the proposed 15-month workplan allowing Lindus (named after James Lind who pioneered the first clinical trial in the 18th century) to gain a dominant position in a Clinical Data Management System Market currently valued at USD1.9 billion with planned exploitation across the UK, EU and U.S.